France - français - ANSES (Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail)

zoetis france - décoquinate - prémélange médicamenteux - antiparasitaire interne, antiprotozoaire - agneau, veau

Canada - français - Health Canada

zoetis canada inc - décoquinate - prémélange médicamenteux - 8g - décoquinate 8g - bétails

Canada - français - Health Canada

may & baker ltd. - décoquinate - poudre - 6% - décoquinate 6% - objet - bétails; volaille

Canada - français - Health Canada

zoetis canada inc - décoquinate - prémélange médicamenteux - 60g - décoquinate 60g - bétails; volaille; mouton

Canada - français - Health Canada

boehringer ingelheim (canada) ltd ltee - empagliflozine - comprimé - 10mg - empagliflozine 10mg - sodium-glucose cotransporter 2 (sglt2) inhibitors

Canada - français - Health Canada

boehringer ingelheim (canada) ltd ltee - empagliflozine - comprimé - 25mg - empagliflozine 25mg - sodium-glucose cotransporter 2 (sglt2) inhibitors

Union européenne - français - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - fibrose kystique - autres produits du système respiratoire - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 et 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 et 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

vertex pharmaceuticals (ch) gmbh - ivacaftorum - comprimés pelliculés - ivacaftorum 150 mg, hypromellosi acetas succinas, natrii laurilsulfas, cellulosum microcristallinum, lactosum monohydricum 167.2 mg, carmellosum natricum conexum, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 3350, talcum, e 132, cera carnauba, drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammonii hydroxidum, pro compresso obducto corresp. natrium 1.82 mg. - la mucoviscidose - synthetika